Hepatorenal Syndrome

Define AKI by either a serum creatinine increase of at least 0.3 mg/dL within 48 hours or an increase of at least 50% from a known or presumed baseline. Use the relative creatinine change rather than an absolute creatinine threshold: low muscle mass can underestimate renal dysfunction in cirrhosis, and smaller creatinine rises carry prognostic significance. PubMed+2PubMedRenal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndromePubMedAcute kidney injury and hepatorenal syndrome in cirrhosisPubMed[Table], Table. Diagnostic Criteria and Classification of Hepatorenal Syndrome in Cirrhosis - StatPearls - NCBI Bookshelf

Immediately assess for shock, active infection, gastrointestinal fluid loss, overdiuresis, recent nephrotoxic medication exposure, and urinary obstruction. HRS-AKI cannot be assigned during shock or with current or recent nephrotoxic drug exposure; these conditions redirect management toward hemodynamic resuscitation, treatment of the precipitant, withdrawal of kidney-toxic agents, or obstruction management. PubMedPubMed[Table], Table. Diagnostic Criteria and Classification of Hepatorenal Syndrome in Cirrhosis - StatPearls - NCBI Bookshelf

Assess intravascular volume and respiratory status before albumin. Traditional ICA criteria require no improvement after albumin 1 g/kg/day, maximum 100 g/day, for 48 hours; the newer ADQI-ICA framework permits earlier diagnosis in euvolemic or hypervolemic patients and favors limiting diagnostic albumin exposure to 24 hours to avoid treatment delay and fluid overload. The 48-hour strategy remains incorporated in established criteria, and a clinically meaningful proportion of responses may occur between 24 and 48 hours. PubMed+2PubMedHepatorenal Syndrome - StatPearls - NCBI BookshelfPubMed[Table], Table. Diagnostic Criteria and Classification of Hepatorenal Syndrome in Cirrhosis - StatPearls - NCBI BookshelfPubMedAcute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. - Abstract

Apply the established ICA diagnostic framework after initial management: decompensated cirrhosis with ascites, AKI that does not improve after 48 hours of albumin expansion at 1 g/kg/day (maximum 100 g/day), absence of shock, no current or recent nephrotoxic medication exposure, and no structural renal disease. This definition operationalizes HRS-AKI as a functional renal syndrome but does not imply that other kidney insults cannot coexist. PubMed+1PubMed[Table], Table. Diagnostic Criteria and Classification of Hepatorenal Syndrome in Cirrhosis - StatPearls - NCBI BookshelfScienceDirectTerlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward - ScienceDirect

Order urine protein quantification, urine microscopy, and renal ultrasonography in every suspected case. Proteinuria no greater than 500 mg/24 hours, microhematuria no greater than 50 RBCs/high-power field, and normal renal ultrasound are required features supporting HRS-AKI; values beyond these thresholds or an abnormal ultrasound should shift the working diagnosis toward intrinsic renal or postrenal disease. PubMedPubMed[Table], Table. Diagnostic Criteria and Classification of Hepatorenal Syndrome in Cirrhosis - StatPearls - NCBI Bookshelf

Fractional excretion of sodium below 0.2% supports HRS-AKI and a value below 0.1% is highly predictive, but this is supportive rather than required. Interpret it as one component of the phenotype rather than as a substitute for urine sediment, protein assessment, imaging, and the response to hemodynamic optimization. PubMedPubMed[Table], Table. Diagnostic Criteria and Classification of Hepatorenal Syndrome in Cirrhosis - StatPearls - NCBI Bookshelf

For patients who meet HRS-AKI criteria and have no major treatment-limiting respiratory or circulatory risk, use terlipressin with albumin. Terlipressin is the first FDA-approved U.S. therapy for HRS-AKI and has stronger evidence for HRS reversal and renal-function improvement than albumin alone, octreotide-based therapy, or the commonly used off-label combination of midodrine and octreotide. Wolters Kluwer+3Wolters KluwerUse of Terlipressin in AKI Associated with Hepatorenal... : Kidney360Wolters KluwerTerlipressin in the treatment of hepatorenal... : MedicinePubMedImproving the Management of Hepatorenal Syndrome–Acute Kidney Injury Using an Updated Guidance and a New Treatment Paradigm - PMCScienceDirectCurrent Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury

Start therapy early in the AKI course. Lower baseline serum creatinine predicts better terlipressin response, whereas bilirubin above 10 mg/dL and a mean arterial pressure increase of less than 5 mm Hg during treatment are associated with poorer response. A lack of hemodynamic or creatinine response should prompt reassessment for persistent infection, structural kidney injury, inadequate effective arterial volume, or advanced liver and circulatory failure rather than automatic continuation without reassessment. Wolters KluwerWolters KluwerUse of Terlipressin in AKI Associated with Hepatorenal... : Kidney360

Use albumin with terlipressin judiciously rather than as unmonitored volume loading. Terlipressin increases afterload and end-diastolic volume while reducing cardiac index; concomitant albumin can unmask cirrhotic cardiac dysfunction and precipitate volume overload or pulmonary edema. Monitor oxygenation and clinical volume status throughout treatment, especially in patients with baseline hypoxemia or advanced acute-on-chronic liver failure. Nature+2NatureSafety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study | Scientific ReportsScienceDirectUnited States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony ConsortiumScienceDirectReal-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome

Refer for liver-transplant evaluation urgently when HRS-AKI is diagnosed or strongly suspected. Liver transplantation is the only curative option for HRS-AKI, and vasoconstrictor therapy functions principally as a bridge to transplantation or to recovery from a reversible precipitating event. Wolters Kluwer+2Wolters KluwerUse of Terlipressin in AKI Associated with Hepatorenal... : Kidney360PubMedAcute kidney injury and hepatorenal syndrome in cirrhosisPubMedAcute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. - Abstract

Escalate care when creatinine continues to rise despite hemodynamic optimization and vasoconstrictor therapy, when respiratory status deteriorates during albumin-terlipressin treatment, or when multiorgan failure develops. Acute-on-chronic liver failure grade 3 and creatinine above 5 mg/dL are particularly consequential because they are both markers of advanced illness and FDA-labeled risk settings for terlipressin. ScienceDirect+1ScienceDirectUnited States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony ConsortiumScienceDirectReal-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome

Consider renal replacement therapy within a transplant-centered plan rather than as a stand-alone response to HRS physiology. Terlipressin can reduce the need for renal replacement therapy in HRS-AKI, but persistent or severe kidney failure may still require support while candidacy and timing for liver transplantation are determined. Wolters Kluwer+1Wolters KluwerUse of Terlipressin in AKI Associated with Hepatorenal... : Kidney360PubMedAcute kidney injury and hepatorenal syndrome in cirrhosis